APIMEDS PHARMACEUTICALS US, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.10 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-05-04.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-05-04
- APIMEDS PHARMACEUTICALS US, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 600.50K shares.
- APIMEDS PHARMACEUTICALS US, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- APIMEDS PHARMACEUTICALS US, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.10M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 600.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | 600.50K shares derived: sum of 2 quarters · filed 2026-05-04 | 1.10M shares 10-K · filed 2026-05-04 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 496.18K shares 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | 496.18K shares 10-Q · filed 2025-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |